Thermo Fisher Scientific (NYSE:TMO) Releases FY 2026 Earnings Guidance

Posted by Mark Dietrich on Jan 30th, 2026

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) updated its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 24.220-24.800 for the period, compared to the consensus EPS estimate of 24.640. The company issued revenue guidance of $46.3 billion-$47.2 billion, compared to the consensus revenue estimate of $46.5 billion.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Argus boosted their price objective on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 target price on the stock in a report on Sunday, December 7th. TD Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, January 7th. Finally, Morgan Stanley lifted their price target on Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $632.63.

Check Out Our Latest Research Report on Thermo Fisher Scientific

Thermo Fisher Scientific Price Performance

TMO stock traded down $10.96 during midday trading on Friday, reaching $581.20. The company had a trading volume of 1,009,959 shares, compared to its average volume of 2,558,182. The company has a market capitalization of $218.36 billion, a P/E ratio of 33.58, a P/E/G ratio of 3.99 and a beta of 0.91. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $643.99. The firm has a 50-day moving average price of $594.14 and a 200-day moving average price of $536.01.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, beating analysts’ consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.95 billion. During the same period last year, the business earned $6.10 earnings per share. The business’s quarterly revenue was up 7.2% on a year-over-year basis. On average, research analysts anticipate that Thermo Fisher Scientific will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock repurchase plan on Thursday, November 6th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 1,058 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total value of $622,379.08. Following the transaction, the vice president directly owned 13,087 shares of the company’s stock, valued at approximately $7,698,558.62. This trade represents a 7.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Frederick M. Lowery sold 6,912 shares of the business’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the sale, the executive vice president directly owned 14,367 shares of the company’s stock, valued at approximately $8,360,731.98. The trade was a 32.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 124,517 shares of company stock worth $72,363,568. 0.33% of the stock is currently owned by corporate insiders.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

Positive Sentiment: Q4 results beat expectations: revenue of $12.21B (+7%) and adjusted EPS $6.57, evidence of continued demand across life‑sciences tools and services. Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results
Positive Sentiment: Strong pharma demand cited as a growth driver for tools and services, supporting near‑term top‑line momentum. Thermo Fisher beats quarterly results estimates on demand for tools from pharma clients
Positive Sentiment: Analyst bullishness: at least one published update reiterates a strong‑buy view and raises a $668 target, arguing the pullback is a buying opportunity given resilient margins and positioning. Thermo Fisher: The Market Is Missing The Point, This Pullback Is A Buy (Rating Update)
Positive Sentiment: Management disclosed potential EPS upside from the Clario acquisition, which could be accretive over time. Thermo Fisher Scientific Discloses How Much Clario Deal Could Add To Its EPS
Neutral Sentiment: Company issued FY‑2026 guidance: revenue $46.3B–$47.2B (4%–6% growth) and EPS $24.22–$24.80; guidance is roughly in line with consensus but wide enough to leave room for execution risk. Thermo Fisher Scientific Inc. 2025 Q4 – Results – Earnings Call Presentation
Neutral Sentiment: Earnings call/transcript and slide deck are available for details on segment trends, margin drivers and one‑time items — useful for modeling FY26 sensitivity. Thermo Fisher Scientific Inc. (TMO) Q4 2025 Earnings Call Transcript
Negative Sentiment: Investors focused on margin pressure and the cautious tone around 2026 profitability, prompting profit‑taking despite the beat. Thermo Fisher stock slides on cautious profit guidance
Negative Sentiment: Market headlines highlighted the outlook update as conservative versus prior investor hopes, which reduced near‑term upside expectations for the stock. Thermo Fisher slips after issuing 2026 outlook (update)

Hedge Funds Weigh In On Thermo Fisher Scientific

Institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after buying an additional 988 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the period. Darwin Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $170,000. Raymond James Financial Inc. lifted its position in shares of Thermo Fisher Scientific by 7.4% in the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after purchasing an additional 53,542 shares during the period. Finally, California State Teachers Retirement System raised its position in shares of Thermo Fisher Scientific by 0.4% in the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after acquiring an additional 2,262 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.